Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00426127
Status:
TERMINATED
Last Update Posted:
2017-12-29
First Post:
2007-01-23
Brief Title:
Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer
Sponsor:
University of Iowa
Organization:
University of Iowa
Study Overview
Official Title:
Phase II Trial of Docetaxel and Liposomal Doxorubicin Doxil Chemotherapy Combined With Enoxaparin in Patients With Advanced Pancreatic Cancer
Status:
TERMINATED
Status Verified Date:
2017-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Inadequate number of eligible patients
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the effects of the treatment combination of the commercially available chemotherapy drugs docetaxel and liposomal doxorubicin and a blood thinner Enoxaparin on pancreatic cancer The main goal of the study is to find out if this combination chemotherapy and enoxaparin increases the number of individuals whose tumors shrink
Detailed Description:
The objective of the study is to determine the safety and efficacy of the combination of docetaxel and liposomal doxorubicin chemotherapy combined with enoxaparin in patients with advanced pancreatic cancer
Docetaxel TAXOTERE belongs to the group of anticancer drugs called mitotic inhibitors Liposomal doxorubicin Doxil is an anthracycline and is thought to prevent nucleic acid synthesis that is needed to make DNA Enoxaparin Lovenox is an anticoagulant We are interested in combining chemotherapy with the blood thinner enoxaparin because there is a scientific link between blood clotting and malignancy
This research is being done to improve on currently available chemotherapy treatments for advanced pancreatic cancer The main goal of the study is to find out if this combination chemotherapy and enoxaparin increases the number of individuals whose tumors shrink Another purpose of this study is to find out how this study treatment effects blood clotting levels in individuals We will also determine the incidence of elevated D-dimer and the effect of this regimen on the level of D-dimer and collect safety data on this regimen
Docetaxel TAXOTERE belongs to the group of anticancer drugs called mitotic inhibitors Liposomal doxorubicin Doxil is an anthracycline and is thought to prevent nucleic acid synthesis that is needed to make DNA Enoxaparin Lovenox is an anticoagulant We are interested in combining chemotherapy with the blood thinner enoxaparin because there is a scientific link between blood clotting and malignancy
This research is being done to improve on currently available chemotherapy treatments for advanced pancreatic cancer The main goal of the study is to find out if this combination chemotherapy and enoxaparin increases the number of individuals whose tumors shrink Another purpose of this study is to find out how this study treatment effects blood clotting levels in individuals We will also determine the incidence of elevated D-dimer and the effect of this regimen on the level of D-dimer and collect safety data on this regimen
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None